Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

September 8, 2022 by Alan Khadavi

Oclacitinib for Atopic Dermatitis (Eczema) in Dogs

Oclacitinib is a potent, safe and rapidly acting anti-itching JAK inhibitor. Oclacitinib was first approved by the US FDA in 2013 to treat eczema and allergic dermatitis in dogs, it is a first generation non-selective JAK inhibitor.

The treatment protocol is 0.4 to 0.6 mg/kg administered orally twice a day for 2 weeks, followed by a once daily administration for maintenance therapy.

There have been recent JAK inhibitors that have come on the market for humans for eczema recently.

Cibinqo Abrocitinib for Atopic Dermatitis by Pfizer

Upadacitinib for Atopic Dermatitis (Eczema)

Oclacitinib works rapidly in allergic dogs, even within hours of administration as with steroids. When changing from twice daily to once daily of oclacitinib there is a rebound in itching that was reported in every clinical trial. Using topical steroids or a short course of steroids at the onset of therapy, prevents or diminishes such a rebound.  The benefit of oclacitinib in terms of decreasing skin lesions is generally noted in 1 to 2 weeks, which is slower than for itch.

The administration of it for dogs is generally considered safe, the side effects mirror those of steroids and cyclosporine. Although for humans it could be different.  Because Oclacitinib is an immune suppressant dogs have developed demodicosis due to Demodex canis or papillomavirus infection. Because of this immunosuppressive effect, it is restricted for dogs older than 1 year of age, as giving it to a dog less than 1 can be dangerous as they already have more immature immune systems.

Overall the long term administration of oclacitinib to dogs might be a concern because the immunosuppressive effect could predispose to cancers. However longer studies have not shown that to be of the case yet.

We have written previously about treatment of eczema in dogs with another biologic medication, Nemolizumab for Itching and Atopic Dermatitis.

There is still much to learn about canine atopic dermatitis, nevertheless the knowledge derived from treating atopic dogs with these drugs might prove helpful to allergists with future drugs and drugs that are in the process of entering the market.

Filed Under: atopic dermatitis, biologics, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page